We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
76
DELISTED
NEVRO CORP.
NVRO
$12.5M 0.23%
145,111
+4,563
+3% +$345K
OMCL icon
77
Omnicell
OMCL
$2.07B
$12.4M 0.23%
171,646
+4,931
+3% +$362K
PACB icon
78
Pacific Biosciences
PACB
$438M
$12.2M 0.23%
+2,373,787
New +$13.3M
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.19B
$11.5M 0.21%
194,736
+26,889
+16% +$1.72M
SUPN icon
80
Supernus Pharmaceuticals
SUPN
$2.79B
$11.4M 0.21%
416,600
-50,400
-11% -$1.49M
AMGN icon
81
Amgen
AMGN
$198B
$11.2M 0.21%
57,700
+11,100
+24% +$2.13M
TRHC
82
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$11.1M 0.21%
201,693
+10,518
+6% +$602K
OXFD
83
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$10.6M 0.2%
637,972
+59,357
+10% +$821K
CHNG
84
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$10.4M 0.19%
863,922
-136,078
-14% -$1.87M
MASI
85
DELISTED
Masimo
MASI
$10.2M 0.19%
68,392
+2,800
+4% +$425K
FIT
86
DELISTED
Fitbit, Inc. Class A common stock
FIT
$10.1M 0.19%
2,659,944
-1,036,586
-28% -$3.85M
QDEL icon
87
QuidelOrtho
QDEL
$1.17B
$9.82M 0.18%
160,016
-108,454
-40% -$6.53M
COO icon
88
Cooper Companies
COO
$13.8B
$9.49M 0.18%
127,876
– –
MOH icon
89
Molina Healthcare
MOH
$11.9B
$9.35M 0.17%
85,239
+3,578
+4% +$463K
IDXX icon
90
Idexx Laboratories
IDXX
$44.6B
$9.28M 0.17%
34,134
+1,685
+5% +$469K
ONC
91
BeOne Medicines Ltd
ONC
$32.5B
$8.98M 0.17%
72,100
-20,900
-22% -$2.78M
QTRX icon
92
Quanterix
QTRX
$176M
$8.92M 0.17%
406,101
+8,532
+2% +$238K
HZNP
93
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.8M 0.16%
323,300
+54,800
+20% +$1.42M
HOLX
94
DELISTED
Hologic
HOLX
$7.84M 0.15%
155,208
+7,660
+5% +$377K
XENT
95
DELISTED
Intersect ENT, Inc
XENT
$7.8M 0.15%
458,588
+7,870
+2% +$143K
VEEV icon
96
Veeva Systems
VEEV
$31.7B
$7.77M 0.14%
50,884
+1,294
+3% +$208K
BIIB icon
97
Biogen
BIIB
$30B
$7.53M 0.14%
32,350
+2,800
+9% +$652K
RMD icon
98
ResMed
RMD
$28.4B
$7.38M 0.14%
54,630
+2,004
+4% +$263K
XRAY icon
99
Dentsply Sirona
XRAY
$2.78B
$7.03M 0.13%
131,818
+6,505
+5% +$349K
SGEN
100
DELISTED
Seagen Inc. Common Stock
SGEN
$6.94M 0.13%
81,300
+8,300
+11% +$608K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.